Plus500 expects 2026 results ahead of market forecasts, shares rise
Source: Investing.com

Plus500 said 2026 revenue and EBITDA are expected to exceed current market expectations after Q3 revenue rose 11% to $203.2 million and EBITDA increased 7% to $88.4 million, a 44% margin. New customers grew 27% to 28,747 while acquisition cost fell 14% to $1,150; the company attributed slower year-to-date EBITDA growth to investment and expansion. It ended September debt-free with more than $775 million in cash, paid an $87.4 million dividend and repurchased about $63.5 million of shares; its shares rose 3.6% in London trading.
Analysis
The key signal is improving acquisition efficiency alongside customer growth, but the investment case depends on whether those customers generate repeat trading income—not just whether they are acquired more cheaply. A sustained rise in customer income and revenue per user would support operating leverage; if marketing spend continues to lift acquisition while EBITDA lags, the payoff is being deferred and the shares remain exposed to execution risk.
The U.S. non-OTC business offers diversification from OTC activity and could broaden the addressable customer base. It also brings a different competitive and regulatory structure, so growth there should not be valued as equivalent to established group revenue until retention, monetization and contribution to earnings are clearer. Competitors such as IG and CMC Markets may face pressure to defend customer acquisition economics if Plus500’s reported efficiency persists, but the quarter alone does not establish a durable advantage.
Near term, the positive guidance and buyback may support sentiment, though chasing the initial price gap risks paying for expectations before the next evidence point. Over 1–3 months, watch customer income, active customers and EBITDA conversion. Over 6–18 months, the thesis hinges on U.S. non-OTC retention and whether growth can outpace incremental operating costs. Customer segregated funds should not be treated as corporate liquidity; assess the company using its own balance sheet and cash generation.
Contrarian risk: trading activity is cyclical, and one strong quarter may not demonstrate normalized earnings power. Missing valuation and forward-estimate data prevent a robust claim that the shares are cheap or that the guidance upgrade is fully priced.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
Key Decisions for Investors
- Do not chase the opening gap. Consider a modest long in PLUS only on a post-reaction pullback or after the next update confirms customer-income growth and improved EBITDA conversion; upside depends on durable customer economics, while the main downside is fading trading activity and delayed returns on marketing investment.
- Use IG and CMC Markets as competitive read-throughs, not automatic shorts: compare disclosed customer acquisition costs, retention and revenue per customer before asserting that Plus500 is taking share.
- Set a 1–3 month alert for customer income, active-customer growth and EBITDA relative to revenue. Reduce or abandon the constructive thesis if customer income weakens, acquisition costs reverse higher, or EBITDA conversion continues to deteriorate without evidence of better customer retention.
- For the 6–18 month thesis, track U.S. non-OTC customer retention and earnings contribution, plus regulatory or market-structure changes affecting that business. Verify valuation and current forward estimates before sizing a position; the supplied information is insufficient to establish expected return.
More News
- SpaceX closes $40 billion debt deal for AI chips, Elon Musk says
- More pain may be coming for the AI trade. Why I’m not giving up on it
- Galp raises 2026 guidance after Q3 core profit beats forecasts
- Goldman Sachs slashes Kospi target to 9,000 but still sees over 60% upside
- Roth/MKM downgrades LKQ stock on Europe woes, CEO transition
- Genmab shares jump 13% on colorectal cancer drug trial results